AbbVie’s Reported $10.9 Billion Apogee Deal Puts Pharma M&A and Pipeline Risk in Focus
AbbVie’s reported $10.9 billion Apogee deal highlights pipeline strategy, capital allocation and potential volatility for APGE and ABBV.
Kodiak Sciences Stock Jumps 90% on Positive Phase 3 AMD Data: What Traders Should Watch Next
Kodiak Sciences shares surged as much as 90% premarket after positive Phase 3 AMD data. Here is what…
Zymeworks Updates 2026 Guidance After Finalizing Theravance Biopharma Deal
Zymeworks has updated its 2026 guidance after finalizing its Theravance Biopharma acquisition, givin…
Kodiak Sciences’ KOD Stock Jumps 65% After DAYBREAK Phase 3 Success
Kodiak Sciences shares reached $54.42 in premarket trading after DAYBREAK met primary endpoints for …
AbbVie’s Parkinson’s Drug Approval Gives ABBV Stock a New October Catalyst
FDA approval for Juvmo gives AbbVie a potential post-Humira growth catalyst ahead of its planned Oct…
Mirum’s FDA Approval Puts Rare-Disease Potential in the Spotlight
Mirum Pharmaceuticals’ FDA approval for a rare bone disorder could become an important catalyst for …
Outlook Therapeutics Faces a Second FDA Rejection for ONS-5010
A second Complete Response Letter puts renewed focus on the uncertainty of binary FDA decisions for …
Moderna-Merck Cancer Vaccine Trial Success Gives Investors a New Oncology Catalyst
Moderna and Merck cleared a major Phase 3 hurdle, strengthening the case for individualized cancer v…
Merck’s Oncology Approval Fuels Debate Over a Potential 37% Valuation Discount
Merck’s Welireg-Lenvima approval adds an oncology catalyst as investors weigh a DCF-based 37% underv…
Mirum Shares Gain as FDA Approval Validates Rare-Disease Drug Strategy
Mirum shares rose 1.0% to $90.23 as FDA approval transformed a key regulatory question into a confir…